Dendrite Announces Schering-Plough to Enhance Sales Force Effectiveness and Business Planning Solution With Dendrite's Proven .NET Framework; New Solution to be Deployed to U.S. Pharmaceutical Field Force Users

Business Wire, June 30, 2006

BEDMINSTER, N.J. -- Dendrite International, Inc. (NASDAQ:DRTE), a leading provider of pharmaceutical industry solutions, today announced that Schering Corporation, a subsidiary of Schering-Plough Corporation, has signed a five-year agreement to enhance VISION, its proprietary sales force effectiveness (SFE) and business planning solution, for its U.S.-based pharmaceutical field sales organization. As a result, Dendrite will seamlessly integrate components of its proven .NET framework with Schering-Plough's VISION system to facilitate the sales force in managing customer information and recording call activity.

Dendrite's .NET framework provides compelling capability to make sales representatives and managers more efficient and productive in their selling activities. Field sales organizations can benefit from Dendrite's revolutionary system navigation, built on human-centered design principles that mirror the workflow of the representative. By matching sales force tools to workflow, representatives can maximize the number of prescriber visits and the quality of each prescriber interaction.

Augmenting the expanded capabilities of Schering-Plough's VISION system will be Sample Guardian(TM), Dendrite's integrated home office sample management and reconciliation solution. Pharmaceutical companies benefit from having a flexible and cost effective alternative for tracking, analyzing, reporting, and storing all drug sample activity data. Sample Guardian, and associated custom reports developed together with Dendrite, assists pharmaceutical companies with ongoing efforts to comply with Food and Drug Administration (FDA) and Prescription Drug Marketing Act (PDMA) regulations.

"Leveraging Dendrite for pharma-specific business process enhancements will give Schering-Plough access to the latest and most effective technologies, proven methodologies and best practices, and support through highly trained personnel with extensive pharmaceutical experience, allowing for continued focus on their core business of developing therapies and having a positive impact on patient lives," said Natasha Giordano, president of global accounts for Dendrite.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ:DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry. The Company's clients are located in more than 50 countries and include the world's top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements and the information provided in this press release should not be construed as updating, modifying or confirming the company's most recent financial outlook or guidance.